Related Experiment Video
Updated: Jun 5, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
[Contribution of genotyping in Fabry's disease]
R Froissart1, M Piraud, I Maire
1Laboratoire des Maladies Héréditaires du Métabolisme, Centre de Biologie Est, Hospices Civils de Lyon, Bron, France. roseline.froissart@chu-lyon.fr
Fabry disease, caused by GLA gene mutations, shows extensive molecular diversity. Genetic testing reliably diagnoses males and carrier females, even when biochemical tests are normal.
Area of Science:
- Genetics
- Biochemistry
- Rare Diseases
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Animal Mitochondrial Genetics

